← All organizations

AveXis, Inc.

For profitContributed to NME

Also known as: AveXis, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Sep 1, 2019

Acquired by Novartis on Apr 9, 2018

Timeline

2010s

Jun 1, 2013
AveXis, Inc.— Founded
Apr 9, 2018
Novartis— Acquired By
May 24, 2019
onasemnogene abeparvovec— NDA Organization

Drugs by trial phase (1 distinct, 8 trials)

Phase 4 (1 own, 0 via acquisition)

onasemnogene abeparvovec

Indications

Studied for

Marketed drugs (1)

onasemnogene abeparvovec

Recent trials (11)

NCT03955679CollaboratorN/A—
NCT04042025Lead sponsorPhase 4Sep 1, 2019
NCT04042025Study chairPhase 4Sep 1, 2019
NCT03837184Lead sponsorPhase 3May 15, 2019
NCT03837184Study directorPhase 3May 15, 2019
NCT03461289Lead sponsorPhase 3Aug 29, 2018
NCT03505099Study chairPhase 3Apr 10, 2018
NCT03505099Lead sponsorPhase 3Apr 10, 2018
NCT03381729Lead sponsorPhase 1Dec 14, 2017
NCT03306277Lead sponsorPhase 3Sep 29, 2017
NCT02122952Lead sponsorPhase 1Apr 1, 2014

Details

Founded: Dallas, TX, US Jun 1, 2013
First NDA: May 24, 2019
Last known activity: Sep 1, 2019

Designations held

Orphan drug
Fast track
Priority review
Breakthrough therapy